Scottish Medicines Consortium dasatinib (Sprycel)

in the absence of a submission from the holder of the marketing authorisation:

dasatinb (Sprycel®) is not recommended for use within NHSScotland.

Indication under review: the treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

To read more Press Release articles, click here.